<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20407" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Desmopressin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>McCarty</surname>
            <given-names>Troy S.</given-names>
          </name>
          <aff>Naval Medical Center San Diego</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Troy McCarty declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>22</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20407.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Desmopressin is a drug that acts on the vasopressin receptors of the body. It has many relevant clinical uses, ranging from nocturnal enuresis to hemophilia. While this drug is relatively safe to use, there are certain side effects to be kept in mind for patients receiving the drug, as well as specific contraindications that limit the population that can receive desmopressin. This activity reviews the indications, mechanism of action, contraindications, and adverse effects. It will also explore the proper monitoring of patients on desmopressin and the role of the inter-professional team required to enhance the outcomes for the patients taking the drug.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications to use desmopressin in a patient.</p></list-item><list-item><p>Describe the mechanism of action of desmopressin.</p></list-item><list-item><p>Review the potential adverse effects of desmopressin.</p></list-item><list-item><p>Summarize the role of an integrated inter-professional team involved in the treatment of the patients receiving desmopressin.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20407&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20407">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20407.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Desmopressin&#x000a0;(1-deamino-8-D-arginine vasopressin) is a synthetic analog of vasopressin, aka antidiuretic hormone, created in 1977 and used in the treatment of a wide variety of medical conditions including nocturnal polyuria, hemophilia A, diabetes insipidus, Willebrand disease, uremic bleeding, as well as many off label uses such as an adjunct with hypertonic saline to prevent rapid sodium correction, intracranial hemorrhage associated with varying antiplatelet agents, and trauma resuscitation with active hemorrhage.<xref ref-type="bibr" rid="article-20407.r1">[1]</xref><xref ref-type="bibr" rid="article-20407.r2">[2]</xref><xref ref-type="bibr" rid="article-20407.r3">[3]</xref></p>
        <p>Nocturnal polyuria is a commonly encountered condition seen almost exclusively in the pediatric population, which is responsive to both oral and intranasal desmopressin. Desmopressin is also available to adults who awaken more than two times a night to void.<xref ref-type="bibr" rid="article-20407.r4">[4]</xref></p>
        <p>Hemophilia A is an X-linked autosomal recessive disorder characterized by the deficiency or absence of the clotting factor VIII.<xref ref-type="bibr" rid="article-20407.r5">[5]</xref>&#x000a0;Factor VIII is an integral component of the intrinsic coagulation pathway, which, when combined with von Willebrand factor, produces the active factor VIIIA, the cofactor responsible for transforming factor X to factor Xa. Factor Xa activates IIa (thrombin) to enable fibrin formation, all of which are integral to the coagulation cascade.<xref ref-type="bibr" rid="article-20407.r1">[1]</xref>&#x000a0;As such, a deficiency in factor VIII results in recurrent bleeding, particularly following surgical procedures or extractions.<xref ref-type="bibr" rid="article-20407.r5">[5]</xref>&#x000a0;Patients with hemophilia A are also at increased risk of major bleeding secondary to minor injuries, such as hemarthrosis and immediate and/or delayed bleeding following trauma.<xref ref-type="bibr" rid="article-20407.r5">[5]</xref>&#x000a0;Desmopressin in the intranasal or intravenous form has FDA approval for use in mild to moderate cases of Hemophilia A, substituted with factor VIII.&#x000a0;</p>
        <p>Diabetes insipidus (DI) classically presents with polyuria and polydipsia and can be secondary to multiple other conditions.<xref ref-type="bibr" rid="article-20407.r6">[6]</xref>&#x000a0;The two primary types of diabetes inspidus include nephrogenic and central. Nephrogenic diabetes insipidus indicates the inability of the kidneys to respond to antidiuretic hormone&#x000a0;or can arise secondary to&#x000a0;long-term lithium use or overdose, as well as any multitude of disorders that affect the inherent ability of the kidneys to function optimally.<xref ref-type="bibr" rid="article-20407.r7">[7]</xref><xref ref-type="bibr" rid="article-20407.r8">[8]</xref>&#x000a0;Central diabetes insipidus occurs secondary to the inability of the hypothalamus to create ADH and can occur as a result of central neurologic system or head trauma, CNS tumors such as craniopharyngioma, or germinoma, or destruction of ADH by placental enzymes vasopressinase.<xref ref-type="bibr" rid="article-20407.r9">[9]</xref><xref ref-type="bibr" rid="article-20407.r10">[10]</xref><xref ref-type="bibr" rid="article-20407.r11">[11]</xref>&#x000a0;In both central and nephrogenic diabetes insipidus, the urine cannot be concentrated optimally with water deprivation, and there is a persistent and continuous excretion of hypotonic urine. Desmopressin administration can be utilized to distinguish between central vs. nephrogenic diabetes insipidus, with a positive response noted in central diabetes insipidus, meaning the kidneys respond appropriately to desmopressin with the expected concentration of the urine and increased reabsorption of fluids, resulting in eutonic urine.&#x000a0;</p>
        <p>Uremic platelet dysfunction encompasses multiple pathways and impairments involving uremia, ultimately resulting in platelet dysfunction. While still largely undefined, the most commonly accepted pathogenesis involves platelet dysfunction secondary to impaired platelet adhesiveness, decreased platelet aggregation, and abnormal platelet endothelial interaction. Factors contributing to platelet dysfunction in uremic patients include uremic toxins, anemia, and nitric oxide production.&#x000a0;</p>
        <p>Uremic platelet dysfunction occurs for several reasons, including circulating uremic toxins, platelet aggregation inhibition by increased nitric oxide production, and anemia resulting in turbulent rather than a laminar flow of blood products.<xref ref-type="bibr" rid="article-20407.r12">[12]</xref>&#x000a0;Desmopressin given intravenously has been shown to improve platelet function within 1 hour of administration.<xref ref-type="bibr" rid="article-20407.r13">[13]</xref></p>
        <p>Von Willebrand disease results from a deficiency in von Willebrand factor. This factor is essential in forming the initial platelet plug as a response to subendothelial tissue exposure.<xref ref-type="bibr" rid="article-20407.r1">[1]</xref>&#x000a0;In increasing order of severity, the different types of the disease are Type 1, Type 2B, 2M, and type 3. Indications for desmopressin include the treatment of types 1 and 2M. It is also most effective in treating diseases caused by the variants of Arg1597Gln, Met740Ile, and Tyr1584Cys.<xref ref-type="bibr" rid="article-20407.r14">[14]</xref>&#x000a0;Desmopressin has also been found, in observed cases, to decrease the risk of bleeding complications in pregnant patients suffering from a mild to moderate form of the disease with a von Willebrand factor concentration of less than or equal to 20 IU/dL.<xref ref-type="bibr" rid="article-20407.r15">[15]</xref></p>
        <p>In a limited number of studies of patients with subarachnoid hemorrhage, some have demonstrated enough evidence to consider utilizing a single intravenous dose of desmopressin in patients with intracranial hemorrhage pending neurosurgical intervention.<xref ref-type="bibr" rid="article-20407.r16">[16]</xref>&#x000a0;</p>
        <p>In a select number of patients suffering from severe hyponatremia with a serum sodium less than 120 mEq/L, studies have demonstrated benefit when utilizing intravenous 3 percent saline while simultaneously initiating desmopressin to prevent rapid correction, decreasing the risk of developing osmotic demyelination syndrome.<xref ref-type="bibr" rid="article-20407.r17">[17]</xref></p>
        <p>Desmopressin has also been utilized in trauma resuscitation and post-surgically to receive hemostasis. Several animal studies have demonstrated that desmopressin is useful in treating severe coagulopathy in injured or post-surgical patients.<xref ref-type="bibr" rid="article-20407.r16">[16]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-20407.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Desmopressin is a selective vasopressin V2 receptor agonist present throughout the collecting ducts and distal convoluted tubules of the kidneys.<xref ref-type="bibr" rid="article-20407.r1">[1]</xref><xref ref-type="bibr" rid="article-20407.r18">[18]</xref>&#x000a0;The V2 receptor is a Gs-protein coupled receptor, which, when activated, results in&#x000a0;a signaling cascade of adenyl-cyclase, prompting an increase in cyclic adenosine monophosphate (cAMP) in the renal tubule cells, ultimately resulting in increased water permeability. This activity leads to a decrease in urine volume and an increase in urine osmolality.&#x000a0;</p>
        <p>The signaling cascade resulting in the production of cyclic adenosine monophosphate also induces exocytosis of von Willebrand factor and factor VIII from its storage sites, as well as the Weibel-Palade bodies and the alpha granules of platelets.<xref ref-type="bibr" rid="article-20407.r1">[1]</xref>&#x000a0;Von Willebrand factor functions as the first step in thrombogenesis, acting as the bridging factor of the Gp1b factor on platelets to the subendothelial collagen following tissue injury.<xref ref-type="bibr" rid="article-20407.r1">[1]</xref>&#x000a0;By utilizing synthetic ADH analogs, such as desmopressin, the clotting cascade is facilitated and can result in hemostasis.<xref ref-type="bibr" rid="article-20407.r19">[19]</xref></p>
      </sec>
      <sec id="article-20407.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Desmopressin can be administered intravenously as a subcutaneous injection, intranasal spray, and, most recently, a dissolvable sublingual strip. Due to the latter's superior bioavailability, the tablet form has been discontinued in many countries in favor of intranasal and sublingual forms.<xref ref-type="bibr" rid="article-20407.r7">[7]</xref>&#x000a0;The administration of intravenous and subcutaneous dose forms of the drug are predominantly in the hospital setting. Dosing for both is 0.3 micrograms/kg.&#x000a0;Peak blood concentration after intravenous administration occurs within 30&#x000a0;to 60 minutes and after subcutaneous administration within 60 to 90&#x000a0;minutes.<xref ref-type="bibr" rid="article-20407.r1">[1]</xref></p>
        <p>The intranasal form of vasopressin is frequently a choice when administration occurs&#x000a0;at home.<xref ref-type="bibr" rid="article-20407.r20">[20]</xref>&#x000a0;Each spray typically dispenses 150 micrograms.<xref ref-type="bibr" rid="article-20407.r1">[1]</xref>&#x000a0;The intranasal dosage is directly proportional to the patient's weight, with patients weighing less than 50 kg prescribed one spray, or 150 micrograms, and patients over 50 kg prescribed 2 sprays, or 300 micrograms, every 12&#x000a0;to 24 hours. This form of the drug reaches peak levels in 60&#x000a0;to 90&#x000a0;minutes.<xref ref-type="bibr" rid="article-20407.r1">[1]</xref></p>
        <p>Sublingual desmopressin, also known as desmopressin lyophilisate, is administered as a sublingual melt tablet at 120 micrograms.<xref ref-type="bibr" rid="article-20407.r21">[21]</xref>&#x000a0;It is generally used in the pediatric population due to the ease of administration and the increased bioavailability.</p>
      </sec>
      <sec id="article-20407.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The major adverse effect&#x000a0;of desmopressin for which to monitor is hyponatremia. As desmopressin increases the urine concentration, it can also lead to systemic hyponatremia with physiology similar to the syndrome of inappropriate antidiuretic hormone.<xref ref-type="bibr" rid="article-20407.r22">[22]</xref>&#x000a0;In certain instances, the hyponatremia caused by this drug can precipitate seizures.&#x000a0;The minor adverse effects that may affect individual patients are headaches, tachycardia, and facial flushing.&#x000a0;There have been certain instances where patients receiving desmopressin have suffered from strokes or myocardial infarctions. However, these cases were rare and did not establish with certainty that desmopressin exerted a direct influence in these cases.<xref ref-type="bibr" rid="article-20407.r1">[1]</xref></p>
      </sec>
      <sec id="article-20407.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Hyponatremia is an absolute contraindication to the administration of desmopressin, except for symptomatic hyponatremia warranting aggressive management with the potential for osmotic demyelinating syndrome. Desmopressin acts primarily in the nephron; this drug is contraindicated in patients with renal impairment.<xref ref-type="bibr" rid="article-20407.r22">[22]</xref>&#x000a0;Also, renal function decreases with age; therefore, care is necessary when prescribing this drug in the older population. This drug should also be avoided in younger patients, especially those under the age of 2, as it is difficult to restrict water and fluids in such patients.<xref ref-type="bibr" rid="article-20407.r1">[1]</xref>&#x000a0;Additionally, this drug is ineffective in patients suffering from type 3 von Willebrand disease; therefore, these patients should not receive the drug.<xref ref-type="bibr" rid="article-20407.r1">[1]</xref>&#x000a0;Finally, patients suffering from thrombocytopenic purpura should not receive desmopressin, as it can precipitate a thrombotic event.<xref ref-type="bibr" rid="article-20407.r1">[1]</xref>&#x000a0;Lastly, desmopressin is contraindicated in patients with&#x000a0;known hypersensitivity to desmopressin acetate.</p>
      </sec>
      <sec id="article-20407.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Desmopressin is generally well-tolerated in most patients. There are a few instances where patients require monitoring for adverse effects of the drug. Patients receiving desmopressin need monitoring for the occurrence of hyponatremia.<xref ref-type="bibr" rid="article-20407.r23">[23]</xref> Symptoms of hyponatremia include nausea, confusion, or altered mental status.<xref ref-type="bibr" rid="article-20407.r24">[24]</xref>&#x000a0;As patients age, they should also be continually monitored for declining renal function, as the therapeutic index and clearance of the drug will change according to the renal function.&#x000a0;</p>
      </sec>
      <sec id="article-20407.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>There is no known antidote to an overdose of desmopressin. The most worrisome complication to result from an overdose is water intoxication. This condition would result in a delayed loss of consciousness and seizures in some instances.&#x000a0;Patients require immediate admission to the intensive care unit to be monitored and have electrolyte correction.<xref ref-type="bibr" rid="article-20407.r25">[25]</xref></p>
      </sec>
      <sec id="article-20407.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Desmopressin is a relatively safe drug for use, but it still requires the efforts of an interprofessional healthcare team for optimal therapeutic success. This team will include clinicians, specialists, mid-level practitioners, nurses, and pharmacists, coordinating their activities and sharing information to achieve the best patient outcomes. [Level 5]&#x000a0;</p>
        <p>Patients receiving desmopressin to treat hemophilia A or von Willebrand disease can remain at risk of bleeding. As such, these patients require an integrated and cohesive team of specialists consisting of the primary care physician, hematologist, and, in some instances, a gynecologist and geneticist. The primary care physician must ensure that the patients are regularly following up with a hematologist or a hemophilia treatment center. In cases of pregnancy, a woman can receive genetic counseling either before becoming pregnant or later on during the pregnancy.<xref ref-type="bibr" rid="article-20407.r5">[5]</xref>&#x000a0;Parents with children suffering from these disorders must understand the complications of the disease and the proper administration of the medication&#x000a0;in the case of an emergency.</p>
      </sec>
      <sec id="article-20407.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20407&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20407">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20407/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20407">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20407.s11">
        <title>References</title>
        <ref id="article-20407.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ozg&#x000f6;nenel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rajpurkar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lusher</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>How do you treat bleeding disorders with desmopressin?</article-title>
            <source>Postgrad Med J</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>83</volume>
            <issue>977</issue>
            <fpage>159</fpage>
            <page-range>159-63</page-range>
            <pub-id pub-id-type="pmid">17344569</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20407.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Herschkowitz</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Low-Dose Desmopressin Nasal Spray and FDA Approval.</article-title>
            <source>JAMA</source>
            <year>2017</year>
            <month>Sep</month>
            <day>19</day>
            <volume>318</volume>
            <issue>11</issue>
            <fpage>1070</fpage>
            <page-range>1070-1071</page-range>
            <pub-id pub-id-type="pmid">28975296</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20407.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wi&#x0015b;niewski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Qi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kraus</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ly</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Srinivasan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tariga</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Croston</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>La</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wi&#x0015b;niewska</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ortiz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Laporte</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rivi&#x000e8;re</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Neyer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hargrove</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Schteingart</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Discovery of Potent, Selective, and Short-Acting Peptidic V<sub>2</sub> Receptor Agonists.</article-title>
            <source>J Med Chem</source>
            <year>2019</year>
            <month>May</month>
            <day>23</day>
            <volume>62</volume>
            <issue>10</issue>
            <fpage>4991</fpage>
            <page-range>4991-5005</page-range>
            <pub-id pub-id-type="pmid">31022340</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20407.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <article-title>Desmopressin (Nocdurna and Noctiva) for nocturnal polyuria.</article-title>
            <source>Med Lett Drugs Ther</source>
            <year>2019</year>
            <month>Mar</month>
            <day>25</day>
            <volume>61</volume>
            <issue>1568</issue>
            <fpage>46</fpage>
            <page-range>46-48</page-range>
            <pub-id pub-id-type="pmid">31022158</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20407.r5">
          <label>5</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Konkle</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Nakaya Fletcher</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Hemophilia A</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Bean</surname>
                <given-names>LJH</given-names>
              </name>
              <name>
                <surname>Gripp</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2000</year>
            <month>9</month>
            <day>21</day>
            <pub-id pub-id-type="pmid">20301578</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20407.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Iorgi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Morana</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Napoli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Allegri</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maghnie</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Management of diabetes insipidus and adipsia in the child.</article-title>
            <source>Best Pract Res Clin Endocrinol Metab</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>415</fpage>
            <page-range>415-36</page-range>
            <pub-id pub-id-type="pmid">26051300</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20407.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chanson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Salenave</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Treatment of neurogenic diabetes insipidus.</article-title>
            <source>Ann Endocrinol (Paris)</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>72</volume>
            <issue>6</issue>
            <fpage>496</fpage>
            <page-range>496-9</page-range>
            <pub-id pub-id-type="pmid">22071315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20407.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ott</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Forss&#x000e9;n</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Werneke</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Lithium treatment, nephrogenic diabetes insipidus and the risk of hypernatraemia: a retrospective cohort study.</article-title>
            <source>Ther Adv Psychopharmacol</source>
            <year>2019</year>
            <volume>9</volume>
            <fpage>2045125319836563</fpage>
            <pub-id pub-id-type="pmid">31007893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20407.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alharfi</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Fraser</surname>
                <given-names>DD</given-names>
              </name>
            </person-group>
            <article-title>Central diabetes insipidus in pediatric severe traumatic brain injury.</article-title>
            <source>Pediatr Crit Care Med</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>203</fpage>
            <page-range>203-9</page-range>
            <pub-id pub-id-type="pmid">23314181</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20407.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leroy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Karrouz</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Douillard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Do Cao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cortet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>W&#x000e9;meau</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Vantyghem</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Diabetes insipidus.</article-title>
            <source>Ann Endocrinol (Paris)</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>74</volume>
            <issue>5-6</issue>
            <fpage>496</fpage>
            <page-range>496-507</page-range>
            <pub-id pub-id-type="pmid">24286605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20407.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chanson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Salenave</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Diabetes insipidus and pregnancy.</article-title>
            <source>Ann Endocrinol (Paris)</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>77</volume>
            <issue>2</issue>
            <fpage>135</fpage>
            <page-range>135-8</page-range>
            <pub-id pub-id-type="pmid">27172867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20407.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boccardo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Remuzzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Galbusera</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Platelet dysfunction in renal failure.</article-title>
            <source>Semin Thromb Hemost</source>
            <year>2004</year>
            <month>Oct</month>
            <volume>30</volume>
            <issue>5</issue>
            <fpage>579</fpage>
            <page-range>579-89</page-range>
            <pub-id pub-id-type="pmid">15497100</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20407.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mannucci</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Remuzzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pusineri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lombardi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Valsecchi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mecca</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zimmerman</surname>
                <given-names>TS</given-names>
              </name>
            </person-group>
            <article-title>Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia.</article-title>
            <source>N Engl J Med</source>
            <year>1983</year>
            <month>Jan</month>
            <day>06</day>
            <volume>308</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <page-range>8-12</page-range>
            <pub-id pub-id-type="pmid">6401193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20407.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Freitas</surname>
                <given-names>SDS</given-names>
              </name>
              <name>
                <surname>Rezende</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>de Oliveira</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Prezotti</surname>
                <given-names>ANL</given-names>
              </name>
              <name>
                <surname>Renni</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Corsini</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Amorim</surname>
                <given-names>MVA</given-names>
              </name>
              <name>
                <surname>Matosinho</surname>
                <given-names>CGR</given-names>
              </name>
              <name>
                <surname>Carvalho</surname>
                <given-names>MRS</given-names>
              </name>
              <name>
                <surname>Chaves</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Genetic variants of VWF gene in type 2 von Willebrand disease.</article-title>
            <source>Haemophilia</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>e78</fpage>
            <page-range>e78-e85</page-range>
            <pub-id pub-id-type="pmid">30817071</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20407.r15">
          <label>15</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Goodeve</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <chapter-title>von Willebrand Disease</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Bean</surname>
                <given-names>LJH</given-names>
              </name>
              <name>
                <surname>Gripp</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2009</year>
            <month>6</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">20301765</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20407.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frontera</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Lewin</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Rabinstein</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Aisiku</surname>
                <given-names>IP</given-names>
              </name>
              <name>
                <surname>Alexandrov</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Del Zoppo</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Peerschke</surname>
                <given-names>EI</given-names>
              </name>
              <name>
                <surname>Stiefel</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Teitelbaum</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Wartenberg</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Zerfoss</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: Executive Summary. A Statement for Healthcare Professionals From the Neurocritical Care Society and the Society of Critical Care Medicine.</article-title>
            <source>Crit Care Med</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>44</volume>
            <issue>12</issue>
            <fpage>2251</fpage>
            <page-range>2251-2257</page-range>
            <pub-id pub-id-type="pmid">27858808</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20407.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rafat</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schortgen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gaudry</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bertrand</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Miguel-Montanes</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Labb&#x000e9;</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ricard</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Hajage</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dreyfuss</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Use of desmopressin acetate in severe hyponatremia in the intensive care unit.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>229</fpage>
            <page-range>229-37</page-range>
            <pub-id pub-id-type="pmid">24262506</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20407.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Narayen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mandal</surname>
                <given-names>SN</given-names>
              </name>
            </person-group>
            <article-title>Vasopressin receptor antagonists and their role in clinical medicine.</article-title>
            <source>Indian J Endocrinol Metab</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>183</fpage>
            <page-range>183-91</page-range>
            <pub-id pub-id-type="pmid">22470853</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20407.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mannucci</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Levi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Prevention and treatment of major blood loss.</article-title>
            <source>N Engl J Med</source>
            <year>2007</year>
            <month>May</month>
            <day>31</day>
            <volume>356</volume>
            <issue>22</issue>
            <fpage>2301</fpage>
            <page-range>2301-11</page-range>
            <pub-id pub-id-type="pmid">17538089</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20407.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaminetsky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dmochowski</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>MacDiarmid</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Abrams</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wein</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of SER120 Nasal Spray in Patients with Nocturia: Pooled Analysis of 2 Randomized, Double-Blind, Placebo Controlled, Phase 3 Trials.</article-title>
            <source>J Urol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>200</volume>
            <issue>3</issue>
            <fpage>604</fpage>
            <page-range>604-611</page-range>
            <pub-id pub-id-type="pmid">29654805</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20407.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gasthuys</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vermeulen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Croubels</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Millecam</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schauvliege</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>van Bergen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>De Bruyne</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vande Walle</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Devreese</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Population Pharmacokinetic Modeling of a Desmopressin Oral Lyophilisate in Growing Piglets as a Model for the Pediatric Population.</article-title>
            <source>Front Pharmacol</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>41</fpage>
            <pub-id pub-id-type="pmid">29445339</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20407.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lim</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Siow</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Choo</surname>
                <given-names>JCJ</given-names>
              </name>
              <name>
                <surname>Chawla</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chin</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Kee</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Foo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Desmopressin for the prevention of bleeding in percutaneous kidney biopsy: efficacy and hyponatremia.</article-title>
            <source>Int Urol Nephrol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>51</volume>
            <issue>6</issue>
            <fpage>995</fpage>
            <page-range>995-1004</page-range>
            <pub-id pub-id-type="pmid">31028561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20407.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agers&#x000f8;</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Seiding Larsen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Riis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>L&#x000f6;vgren</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Karlsson</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Senderovitz</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2004</year>
            <month>Oct</month>
            <volume>58</volume>
            <issue>4</issue>
            <fpage>352</fpage>
            <page-range>352-8</page-range>
            <pub-id pub-id-type="pmid">15373927</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20407.r24">
          <label>24</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Shrimanker</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bhattarai</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Electrolytes</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>24</day>
            <pub-id pub-id-type="pmid">31082167</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20407.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Segal-Kuperschmit</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dali-Gotfrid</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Luder</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Water intoxication following desmopressin overdose].</article-title>
            <source>Harefuah</source>
            <year>1997</year>
            <month>Apr</month>
            <day>01</day>
            <volume>132</volume>
            <issue>7</issue>
            <fpage>465</fpage>
            <page-range>465-7, 527, 526</page-range>
            <pub-id pub-id-type="pmid">9153915</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
